Atossa Therapeutics (NASDAQ:ATOS) Announces Earnings Results

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) announced its quarterly earnings data on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, Yahoo Finance reports.

Atossa Therapeutics Trading Up 7.6 %

ATOS traded up $0.14 during trading on Wednesday, hitting $1.98. 1,055,749 shares of the stock were exchanged, compared to its average volume of 1,046,335. Atossa Therapeutics has a 1-year low of $0.59 and a 1-year high of $2.11. The stock has a fifty day moving average price of $1.17 and a two-hundred day moving average price of $0.90.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of Atossa Therapeutics by 10.8% in the first quarter. Renaissance Technologies LLC now owns 936,070 shares of the company’s stock valued at $679,000 after purchasing an additional 91,300 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Atossa Therapeutics by 29.3% in the fourth quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock valued at $395,000 after purchasing an additional 101,690 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Atossa Therapeutics by 4.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 313,912 shares of the company’s stock valued at $393,000 after purchasing an additional 14,481 shares during the period. Bank of Montreal Can acquired a new position in shares of Atossa Therapeutics in the second quarter valued at approximately $365,000. Finally, Northern Trust Corp increased its holdings in shares of Atossa Therapeutics by 6.2% in the fourth quarter. Northern Trust Corp now owns 227,922 shares of the company’s stock valued at $201,000 after purchasing an additional 13,280 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ATOS. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Atossa Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research note on Friday, January 12th.

Get Our Latest Stock Report on Atossa Therapeutics

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Read More

Earnings History for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.